ADORA2A and neoplasm: Mice with genetic knockout of the A2A adenosine receptor have increased ability to reject tumors [222], a more robust population of tumor antigen-specific CD8+ T cells in draining lymph nodes, and enhanced response to anti PD-1 therapy.